{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:08:03Z","timestamp":1788869283671,"version":"build-2803163510"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Ovarian cancer remains one of the leading causes of cancer-related mortality among women because of its asymptomatic early course, delayed diagnosis, and frequent presentation at advanced stages. Germline and somatic mutations in the BRCA1 and BRCA2 genes significantly increase the risk of ovarian cancer by impairing homologous recombination DNA repair, resulting in genomic instability. Beyond their role in carcinogenesis, BRCA mutations have become important prognostic and predictive biomarkers, influencing treatment response and clinical outcomes. This review summarizes current evidence regarding the impact of BRCA1\/2 status on prognosis and therapeutic strategies in ovarian cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A literature review was conducted using the PubMed and Scopus databases. English-language articles published between 2016 and 2026 were identified using combinations of the keywords\n                      <jats:italic>ovarian cancer<\/jats:italic>\n                      ,\n                      <jats:italic>BRCA1<\/jats:italic>\n                      ,\n                      <jats:italic>BRCA2<\/jats:italic>\n                      ,\n                      <jats:italic>PARP inhibitors<\/jats:italic>\n                      ,\n                      <jats:italic>homologous recombination deficiency<\/jats:italic>\n                      , and\n                      <jats:italic>treatment<\/jats:italic>\n                      . Original studies, systematic reviews, meta-analyses, and relevant clinical trials were included.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The available evidence demonstrates that patients carrying BRCA1 or BRCA2 mutations generally experience improved progression-free survival and, in many studies, prolonged overall survival compared with non-carriers. This survival advantage is largely attributed to increased sensitivity to platinum-based chemotherapy and the efficacy of PARP inhibitors, which exploit synthetic lethality in homologous recombination-deficient tumors. The literature also emphasizes the importance of universal BRCA testing to optimize treatment selection, identify candidates for maintenance PARP inhibitor therapy, and facilitate genetic counseling. In addition, emerging mechanisms of resistance to PARP inhibitors remain a significant therapeutic challenge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>BRCA1\/2 mutation status is a key biomarker in the management of ovarian cancer, supporting personalized treatment strategies and improving patient outcomes. Further research is needed to identify novel predictive biomarkers, overcome therapeutic resistance, and develop more effective targeted therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1899836","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:11:00Z","timestamp":1788865860000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic and therapeutic implications of BRCA1 and BRCA2 mutations in ovarian cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Weronika","family":"Pawul","sequence":"first","affiliation":[{"name":"Student\u2019s Scientific Association at the I Chair and Department of Gynaecological Oncology and Gynaecology, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Opoka","sequence":"additional","affiliation":[{"name":"Student\u2019s Scientific Association at the I Chair and Department of Gynaecological Oncology and Gynaecology, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Dusza","sequence":"additional","affiliation":[{"name":"Student\u2019s Scientific Association at the I Chair and Department of Gynaecological Oncology and Gynaecology, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Blajerski","sequence":"additional","affiliation":[{"name":"Student\u2019s Scientific Association at the I Chair and Department of Gynaecological Oncology and Gynaecology, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Orzelska","sequence":"additional","affiliation":[{"name":"Student\u2019s Scientific Association at the I Chair and Department of Gynaecological Oncology and Gynaecology, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Gierulska","sequence":"additional","affiliation":[{"name":"Student\u2019s Scientific Association at the I Chair and Department of Gynaecological Oncology and Gynaecology, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Ku\u0142ak","sequence":"additional","affiliation":[{"name":"I Chair and Department of Gynaecological Oncology and Gynaecology, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Tarkowski","sequence":"additional","affiliation":[{"name":"I Chair and Department of Gynaecological Oncology and Gynaecology, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30561","article-title":"Aetiology, epidemiology, histopathology, classification, detailed evaluation, and treatment of ovarian cancer","volume":"14","author":"Zamwar","year":"2022","journal-title":"Cureus"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26104611","article-title":"Ovarian cancer-epidemiology, classification, pathogenesis, treatment, and estrogen receptors' molecular backgrounds","volume":"26","author":"Smolarz","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.5114\/pm.2023.128661","article-title":"Epidemiology and risk factors for ovarian cancer","volume":"22","author":"Ali","year":"2023","journal-title":"Menopause Review\/Przegl\u0105d Menopauzalny"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.828303","article-title":"Pyroptosis: a developing foreland of ovarian cancer treatment","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231912041","article-title":"Molecular biomarkers for the early detection of ovarian cancer","volume":"23","author":"Zhang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B6","first-page":"1993","article-title":"BRCA1- and BRCA2-associated hereditary breast and ovarian cancer","volume-title":"Genereviews\u00ae [Internet]","author":"Petrucelli","year":"1998"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/genes12071050","article-title":"Differences in ovarian and other cancers risks by population and BRCA mutation location","volume":"12","author":"Sekine","year":"2021","journal-title":"Genes (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/1758834017714993","article-title":"BRCA mutation in ovarian cancer: testing, implications and treatment considerations","volume":"9","author":"Neff","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1101\/gad.352083.124","article-title":"BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality","volume":"39","author":"Khalizieva","year":"2025","journal-title":"Genes Dev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2021-0135","article-title":"Real-world treatment patterns and outcomes in platinum-sensitive recurrent high-grade serous ovarian cancer patients","volume":"11","author":"Moya-Alarc\u00f3n","year":"2022","journal-title":"J Comp Eff Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2147\/IJGM.S445660","article-title":"Association between germline BRCA1\/2 gene variants and clinicopathological features of ovarian cancer","volume":"17","author":"Luo","year":"2024","journal-title":"Int J Gen Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.21037\/cco-20-34","article-title":"Epidemiology of ovarian cancer","volume":"9","author":"Gaona-Luviano","year":"2020","journal-title":"Chin Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57090905","article-title":"BRCA genes and related cancers: a meta-analysis from epidemiological cohort studies","volume":"57","author":"Lee","year":"2021","journal-title":"Med (Kaunas)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-020-01148-2","article-title":"Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis","volume":"28","author":"Yoshida","year":"2021","journal-title":"Breast Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.04.010","article-title":"Association of gene variant type and location with breast cancer risk in the general population","volume":"36","author":"Akamandisa","year":"2025","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/genes12071050","article-title":"Differences in ovarian and other cancers risks by population and BRCA mutation location","volume":"12","author":"Sekine","year":"2021","journal-title":"Genes (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw142","article-title":"BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer","volume":"27","author":"Moschetta","year":"2016","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100793","article-title":"Homologous recombination gene mutations in uterine serous cancer: a phenotype of the hereditary breast and ovarian cancer syndrome","volume":"8","author":"Ahsan","year":"2023","journal-title":"ESMO Open"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05496-1","article-title":"Ovarian cancer mutational processes drive site-specific immune evasion","volume":"612","author":"V\u00e1zquez-Garc\u00eda","year":"2022","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4068","article-title":"Structural variants at the BRCA1\/2 loci are a common source of homologous repair deficiency in high-grade serous ovarian carcinoma","volume":"27","author":"Ewing","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S206817","article-title":"Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome","volume":"11","author":"Ashour","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2020.03.001","article-title":"Pathologic chemotherapy response score in epithelial ovarian cancer: surgical, genetic, and survival considerations","volume":"34","author":"Barrington","year":"2020","journal-title":"Surg Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009380","article-title":"Association of BRCA1\/2 mutations with ovarian cancer prognosis: an updated meta-analysis","volume":"97","author":"Huang","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2021-003116","article-title":"BRCA status and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score","volume":"32","author":"Ergasti","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.14789\/jmj.JMJ22-0044-R","article-title":"Cutting-edge treatment for gynecological Malignancies","volume":"69","author":"Terao","year":"2023","journal-title":"Juntendo Iji Zasshi"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00016","article-title":"Role of BRCA mutations in the modulation of response to platinum therapy","volume":"8","author":"Mylavarapu","year":"2018","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11010119","article-title":"Platinum resistance in ovarian cancer: role of DNA repair","volume":"11","author":"Damia","year":"2019","journal-title":"Cancers"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1225","article-title":"Effectiveness of PARP inhibitor maintenance therapy in ovarian cancer by BRCA1\/2 and a scar-based HRD signature in real-world practice","volume":"30","author":"Richardson","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082357","article-title":"PARP inhibitors in breast and ovarian cancer","volume":"15","author":"Wang","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40364-025-00818-7","article-title":"Therapeutic landscape of ovarian cancer: recent advances and emerging therapies","volume":"13","author":"Wang","year":"2025","journal-title":"biomark Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG-3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0271-y","article-title":"Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","volume":"119","author":"Friedlander","year":"2018","journal-title":"Br J Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ygyno.2025.03.018","article-title":"ENGOT-OV16\/NOVA trial of niraparib in recurrent ovarian cancer: survival and long-term safety","volume":"196","author":"Matulonis","year":"2025","journal-title":"Gynecol Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115584","article-title":"Overall survival and long-term safety from the randomized phase 3 ARIEL3 trial of rucaparib maintenance treatment in patients with recurrent ovarian cancer","volume":"223","author":"Coleman","year":"2025","journal-title":"Eur J Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjog.2026.01.006","article-title":"Immunology and therapeutic strategies in ovarian cancer","volume":"65","author":"Chang","year":"2026","journal-title":"Taiwan J Obstet Gynecol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13045-025-01686-2","article-title":"Mirvetuximab soravtansine: current and future applications","volume":"18","author":"Kong","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100149","article-title":"Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"6","author":"Kim","year":"2021","journal-title":"ESMO Open"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/cells11030539","article-title":"Hereditary ovarian carcinoma: cancer pathogenesis looking beyond BRCA1 and BRCA2","volume":"11","author":"Samuel","year":"2022","journal-title":"Cells"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00156-1","article-title":"Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers with personal history of breast cancer: a retrospective cohort study using linked electronic health records","volume":"26","author":"Hassan","year":"2025","journal-title":"Lancet Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-020-01148-2","article-title":"Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis","volume":"28","author":"Yoshida","year":"2021","journal-title":"Breast Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1158\/1078-0432.CCR-23-2249","article-title":"Olaparib plus Durvalumab, with or without Bevacizumab, as treatment in PARP inhibitor-na\u00efve platinum-sensitive relapsed ovarian cancer: A phase II multi-cohort study","volume":"30","author":"Drew","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.02.014","article-title":"Mechanism of PARP inhibitor resistance and potential overcoming strategies","volume":"11","author":"Fu","year":"2023","journal-title":"Genes Dis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2019.50","article-title":"Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology","volume":"2","author":"Mweempwa","year":"2019","journal-title":"Cancer Drug Resist"},{"key":"B57","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.716467","article-title":"Melphalan as a promising treatment for BRCA-related ovarian carcinoma","volume":"11","author":"Conteduca","year":"2021","journal-title":"Front Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1162665","article-title":"Olaparib and advanced ovarian cancer: summary of the past and looking into the future","volume":"14","author":"Maiorano","year":"2023","journal-title":"Front Pharmacol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251343973","article-title":"Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer","volume":"17","author":"Mukherjee","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2449782","article-title":"Physician knowledge, use, and perceptions of genetic biomarker testing for the management of patients with newly diagnosed advanced ovarian cancer: an international physician survey","volume":"21","author":"Banerjee","year":"2025","journal-title":"Future Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061625","article-title":"Women's priorities towards ovarian cancer testing: a best-worst scaling study","volume":"12","author":"Hall","year":"2022","journal-title":"BMJ Open"},{"key":"B65","unstructured":"Clinicaltrials.Gov Identifier: NCT06972693\n          \n          2024"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102386","article-title":"Liquid biopsy in the clinical management of high-grade serous epithelial ovarian cancer-current use and future opportunities","volume":"13","author":"Paracchini","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1899836\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:11:02Z","timestamp":1788865862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1899836\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":66,"alternative-id":["10.3389\/fonc.2026.1899836"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1899836","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1899836"}}